Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770048 | 1.00 | ATM (0.43) | ATMAGTR2MMP2ANPEPUCHL1 | |
| SCHEMBL29253522 | 1.00 | ATM (0.43) | ATMAGTR2MMP2ANPEPUCHL1 | |
| SCHEMBL6596413 | 1.00 | ATM (0.43) | ATMAGTR2MMP2ANPEPUCHL1 | |
| SCHEMBL5160994 | 1.00 | ATM (0.43) | ATMAGTR2MMP2ANPEPUCHL1 | |
| SCHEMBL19064872 | 1.00 | ATM (0.43) | ATMAGTR2MMP2ANPEPUCHL1 | |
| SCHEMBL25303244 | 0.87 | ATM (0.34) | ATMMMP2ANPEPUCHL1TSHR | |
| SCHEMBL7348060 | 0.87 | ATM (0.59) | ATMAGTR2MMP2ANPEP | |
| SCHEMBL7348056 | 0.87 | ATM (0.59) | ATMAGTR2MMP2ANPEP | |
| SCHEMBL2607041 | 0.87 | ATM (0.59) | ATMAGTR2MMP2ANPEP | |
| SCHEMBL25304982 | 0.87 | ATM (0.34) | ATMMMP2ANPEPUCHL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397664-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-07-10 | — | — | EP | disclosed |
| US-20240166660-A1 | KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20210380604-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| EP-3880208-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3853234-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | Nikang Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | PFIZER INC | 2009-09-03 | — | — | US | disclosed |
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | WARNER-LAMBERT COMPANY LLC | 2008-11-20 | — | — | US | disclosed |
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
| US-7407974-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407972-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC | 2006-11-23 | — | — | US | disclosed |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234263-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | ATM 560/4885AGTR2 988/4885MMP2 2512/4885 |
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | TFPI, F11, F2 | ATM 1254/4885AGTR2 2183/4885MMP2 190/4885 |
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | PPID, PREP, P4HA1 | ATM 4078/4885AGTR2 376/4885MMP2 2005/4885 |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | ATM 1274/4885AGTR2 831/4885MMP2 202/4885 |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | ATM 1055/4885AGTR2 1689/4885MMP2 3156/4885 |
| US-20240166660-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 2707/4885AGTR2 270/4885MMP2 2478/4885 |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | ATM 1449/4885AGTR2 2444/4885MMP2 240/4885 |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | ATM 2705/4885AGTR2 1034/4885MMP2 102/4885 |
| US-20210380604-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPN2 | ATM 889/4885AGTR2 1461/4885MMP2 2956/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885AGTR2 1536/4885MMP2 2794/4885 |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | ATM 1449/4885AGTR2 2444/4885MMP2 240/4885 |
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PREP, P4HA1, PPID | ATM 4252/4885AGTR2 451/4885MMP2 3368/4885 |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | ATM 1055/4885AGTR2 1689/4885MMP2 3156/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885AGTR2 1536/4885MMP2 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.